The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Market Overview

The peptide and oligonucleotide contract development and manufacturing organization (CDMO) market has experienced significant growth in recent years.

• 2023 Market Size: $1.93 billion.
• 2024 Forecast: Expected to reach $2.16 billion, growing at a compound annual growth rate (CAGR) of 11.8%.
• 2028 Projection: Anticipated to reach $3.39 billion, with a CAGR of 12.0%.

Historical Growth Drivers

The growth in the historical period can be attributed to several factors:

• Therapeutic Demand: Increased demand for therapeutic agents.
• Technological Advancements: Progress in synthesis and manufacturing technologies.
• Personalized Medicine: Rising trends in personalized medicine.
• Regulatory Guidelines: Stricter regulatory frameworks boosting market confidence.
• Focus on Antivirals and mRNA: Enhanced focus on antiviral peptides and mRNA vaccines, showcasing the potential of oligonucleotides in vaccine development.

Read More On The Peptide And Oligonucleotide CDMO Market Report 2024 – https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Future Growth Drivers

The projected growth in the coming years is driven by:

• Personalized Medicine: Continued demand for tailored therapeutic solutions.
• Biotechnology Advancements: Innovations in biotechnology.
• Expanding Applications: Broader applications of peptides and oligonucleotides.
• Outsourcing: Increasing trend of outsourcing manufacturing and development.
• Chronic Diseases: Growing burden of chronic diseases requiring advanced therapies.

Major Trends

Several key trends are shaping the market:

• Personalized Therapies: Emphasis on custom treatments.
• Technological Advancements: Ongoing improvements in technology.
• Quality Control Challenges: Ensuring high-quality production standards.
• Global Expansion: Companies expanding their global footprint.
• Collaboration: Increased partnerships among biopharmaceutical companies.

Personalized Medicine: A Key Growth Driver

Personalized medicine is a significant growth driver in the peptide and oligonucleotide CDMO market.

• Tailored Treatments: Medical decisions and treatments based on individual characteristics such as genetics, environment, and lifestyle.
• Genomic Technologies: Advancements in genomic technologies facilitating personalized approaches.
• Disease Mechanisms: Better understanding of molecular-level disease mechanisms.
• FDA Approvals: For instance, the FDA approved 16 new personalized treatments for rare diseases in February 2024, up from 6 in 2022.

Strategic Partnerships Enhance Capabilities

Companies in the peptide and oligonucleotide CDMO market are forming strategic partnerships to boost their capabilities.

• Collaborative Agreements: Partnerships focused on developing and manufacturing peptide-based therapeutics.
• Example: In May 2023, PolyPeptide Group AG partnered with Numaferm GmbH to leverage their respective strengths in manufacturing and sustainable peptide production.

EUROAPI’s Acquisition of BianoGMP

EUROAPI made a strategic acquisition to strengthen its market position.

• Acquisition: In May 2024, EUROAPI acquired BianoGMP to enhance its capabilities in oligonucleotide CDMO services.
• Impact: This acquisition complements EUROAPI’s existing capacities, particularly in Frankfurt, and bolsters its market position.

Market Segmentation

The peptide and oligonucleotide CDMO market is segmented by product, service type, application, and end user.

• By Product: Peptides, Oligonucleotides.
• By Service Type: Contract Development, Contract Manufacturing.
• By Application: Therapeutics, Research Applications, Diagnostics, Other Applications.
• By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users.

Regional Insights

• North America: The largest region in the peptide and oligonucleotide CDMO market in 2023.
• Asia-Pacific: Expected to be the fastest-growing region during the forecast period, driven by advancements in biotechnology and increasing healthcare investments.

In summary, the peptide and oligonucleotide CDMO market is poised for robust growth, driven by personalized medicine, technological advancements, and strategic partnerships. As the demand for specialized therapeutic agents rises, the market will continue to expand, offering significant opportunities for companies in this sector.

Request for A Sample Of The Global Peptide And Oligonucleotide CDMO Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=15892&type=smp